Outcome of the Meeting of Board of Directors held on Thursday, May 21, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Genpharmasec Limited reported strong financial results for FY2026 ended March 31, 2026. Standalone revenue from operations grew significantly to Rs 13,555.56 Lakhs from Rs 3,296.07 Lakhs in FY2025, representing over 311% growth. Profit after tax stood at Rs 544.96 Lakhs versus Rs 280.04 Lakhs in the prior year, a growth of approximately 95%. The Board approved the audited standalone and consolidated financial results, with Statutory Auditors Bilimoria Mehta & Co. issuing an unmodified (clean) opinion. The company also re-appointed M/s. Abhishek M Agrawal & Co. as Internal Auditor for FY2026-27. Key notes include reclassification of equity shares from Inventories to Financial Investments (FVOCI), and acquisition of Derren Healthcare Private Limited as a subsidiary in July 2025.
The company demonstrated exceptional revenue and profit growth in FY2026, which could be positive for the stock. However, the auditor flagged going concern doubts for two subsidiaries (Derren Healthcare and Clinigenome India) that have incurred losses and face liquidity challenges, adding risk for investors.